Obiltoxaximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | Bacillus anthracis anthrax |
| Clinical data | |
| Trade names | Anthim, Nyxthracis, others |
| Other names | ETI-204 |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6444H9994N1734O2022S44 |
| Molar mass | 145521.59 g·mol−1 |
Obiltoxaximab, sold under the brand name Anthim among others, is a monoclonal antibody medication designed for the treatment of exposure to Bacillus anthracis spores (etiologic agent of anthrax).[5][2][6]
The medication was developed by Elusys Therapeutics, Inc.[2][7]
- ^ "Summary Basis of Decision (SBD) for Anthim". Health Canada. 23 October 2014. Retrieved 29 May 2022.
- ^ a b c "Anthim- obiltoxaximab solution". DailyMed. 9 December 2019. Retrieved 21 September 2020.
- ^ Cite error: The named reference
Nyxthracis EPARwas invoked but never defined (see the help page). - ^ "Nyxthracis Product information". Union Register of medicinal products. Retrieved 3 March 2023.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Obiltoxaximab, American Medical Association.
- ^ Hou AW, Morrill AM (October 2017). "Obiltoxaximab: Adding to the Treatment Arsenal for Bacillus anthracis Infection". The Annals of Pharmacotherapy. 51 (10): 908–913. doi:10.1177/1060028017713029. PMID 28573869. S2CID 39810240.
- ^ "Anthim (obiltoxaximab) Injection". U.S. Food and Drug Administration (FDA). 26 April 2016. Retrieved 18 October 2020.
- "Center for Drug Evaluation and Research: Application Number: 125509Orig1s000: Summary Review" (PDF). Food and Drug Administration.